

**Request for Prior Authorization
CYSTIC FIBROSIS AGENTS, ORAL**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #		Patient name		DOB	
Patient address					
Provider NPI		Prescriber name		Phone	
Prescriber address				Fax	
Pharmacy name		Address		Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI		Pharmacy fax		NDC	

Prior authorization (PA) is required for oral cystic fibrosis agents. Payment will be considered for patients when the following criteria are met:

- 1) Patient meets the FDA approved age; and
- 2) Patient has a diagnosis of cystic fibrosis (CF); and
- 3) Patient has a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene confirmed by an FDA-cleared CF mutation test (attach test results) for which the requested drug is indicated; and
- 4) Prescriber is a CF specialist or pulmonologist; and
- 5) Baseline liver function tests (AST, ALT, and bilirubin) are provided; and
- 6) Requests for Trikafta will not be considered for patients with severe hepatic impairment (Child-Pugh Class C); and
- 7) Will not be used with other CFTR modulator therapies.

If the criteria for coverage are met, an initial authorization will be given for 6 months. Additional approvals will be granted if the following criteria are met:

- 1) Adherence to oral cystic fibrosis therapy is confirmed; and
- 2) Liver function tests (AST, ALT, and bilirubin) are assessed every 3 months during the first year of treatment and annually thereafter.

Non-Preferred

Kalydeco Orkambi Symdeko Trikafta

Strength	Dosage Instructions	Quantity	Days Supply
_____	_____	_____	_____

Diagnosis (Attach copy of FDA-cleared CF mutation test results): _____

Attach copy of baseline liver function test (AST/ALT/bilirubin).

Prescriber Specialty: CF Specialist Pulmonologist Other (specify): _____



FAX Completed Form To
1.877.386.4695

Provider Help Desk
1.866.399.0928

**Request for Prior Authorization
IVACAFOR (KALYDECO™)**
(PLEASE PRINT – ACCURACY IS IMPORTANT)

Will requested medication be used with other CFTR modulator therapies? No Yes

Trifakta Requests:

Does patient have severe hepatic impairment (Child-Pugh Class C)? No Yes

Renewal Requests:

Patient is adherent to oral cystic fibrosis therapy: Yes No

Liver function tests (AST/ALT/bilirubin) are assessed every 3 months during first year of treatment and annually thereafter: Yes No Most recent lab date: _____

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.